Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

136
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
136
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

115
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
115
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

196
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
196
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

115
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
115
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Peer review of the pesticide risk assessment of the active substance <i>Bacillus paralicheniformis</i> strain FMCH001.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance <i>Bacillus subtilis</i> strain FMCH002.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance cymoxanil.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment for the active substance bifenazate in light of confirmatory data submitted.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance proquinazid.

EFSA journal. European Food Safety Authority·2026
Same author

Peer review of the pesticide risk assessment of the active substance metyltetraprole.

EFSA journal. European Food Safety Authority·2026

Related Experiment Video

Updated: Dec 17, 2025

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
05:45

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality

Published on: April 7, 2023

3.4K

Guidance on protocol development for EFSA generic scientific assessments.

, Simon More, Vasileios Bampidis

    EFSA Journal. European Food Safety Authority
    |November 1, 2023
    PubMed
    Summary

    This guidance introduces the APRIO paradigm for formulating scientific assessment questions, enhancing EFSA

    Keywords:
    APRIOPECOPICOgeneric scientific assessmentsguidancemethodsplanningproblem formulationprotocol development

    More Related Videos

    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
    16:02

    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

    Published on: February 10, 2023

    2.7K
    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications
    08:54

    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications

    Published on: November 5, 2020

    13.1K

    Related Experiment Videos

    Last Updated: Dec 17, 2025

    Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
    05:45

    Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality

    Published on: April 7, 2023

    3.4K
    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
    16:02

    Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

    Published on: February 10, 2023

    2.7K
    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications
    08:54

    Development and Testing of Species-specific Quantitative PCR Assays for Environmental DNA Applications

    Published on: November 5, 2020

    13.1K

    Area of Science:

    • Food safety science
    • Risk assessment methodology

    Background:

    • EFSA Strategy 2027 emphasizes the need for robust protocols for scientific assessments.
    • Existing frameworks for protocol development require harmonization and flexibility.

    Purpose of the Study:

    • To provide a harmonized and flexible framework for developing protocols for EFSA generic scientific assessments.
    • To replace the 2020 draft framework for protocol development.

    Main Methods:

    • Introduces the APRIO (Agent, Pathway, Receptor, Intervention, Output) paradigm for problem formulation.
    • Outlines five approaches for specifying evidence needs and methods to answer assessment questions.
    • Includes guidance on uncertainty analysis and a protocol template.

    Main Results:

    • The APRIO paradigm offers a structured approach to translating Terms of Reference into answerable questions.
    • APRIO is adaptable across EFSA domains and aims to harmonize outputs and foster consistency.
    • The guidance details methods for evidence gathering and analysis, including expert judgment and modeling.

    Conclusions:

    • The proposed framework and APRIO paradigm enhance the development of fit-for-purpose protocols for scientific advice.
    • This guidance promotes consistency and adaptability in EFSA's scientific assessment processes.
    • The APRIO paradigm is recommended for its potential to overcome challenges with existing frameworks like PICO/PECO.